Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.

Background And Purpose: A subgroup of salivary duct carcinoma (SDC) harbor overexpression of the androgen receptor (AR), and co-occurring mutations in the - and -genes. The impact of genomic complexity on targeted treatment strategies in advanced cancer is unknown.

Materials And Methods: We analyzed molecular and clinical data from an institutional molecular tumor board (MTB) to identify AR+, / co-mutated SDC.